NDAORALCAPSULE, DELAYED RELEASE
Approved
Aug 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ESOMEPRAZOLE STRONTIUM (esomeprazole strontium) by R-Pharm US is 12. First approved in 2013.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Esomeprazole strontium is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting H+/K+-ATPase in parietal cells. It is used to treat gastroesophageal reflux disease (GERD) and other acid-related conditions. The delayed-release oral capsule formulation delivers the active S-isomer of omeprazole for sustained acid suppression.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable commercial operations and maintenance-focused team structure rather than growth hiring.
Mechanism of Action
12.CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H /K -ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the…
Worked on ESOMEPRAZOLE STRONTIUM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.